@article {DeSouza664, author = {Sherwin DeSouza and Dana Angelini}, title = {Updated guidelines for immune thrombocytopenic purpura: Expanded management options}, volume = {88}, number = {12}, pages = {664--668}, year = {2021}, doi = {10.3949/ccjm.88a.20201}, publisher = {Cleveland Clinic Journal of Medicine}, abstract = {The current American Society of Hematology (ASH) guidelines for the management of patients with immune thrombocytopenic purpura (ITP) are an update to the 2011 guidelines. The updates focus on treating patients with ITP without bleeding in both outpatient and inpatient settings, including those with newly diagnosed, persistent, and chronic ITP refractory to first-line therapy. Recommendations for therapy include corticosteroids, intravenous immunoglobulins, anti-D immunoglobulin, rituximab, splenectomy, and thrombopoietin-receptor agonists, as well as observation.}, issn = {0891-1150}, URL = {https://www.ccjm.org/content/88/12/664}, eprint = {https://www.ccjm.org/content/88/12/664.full.pdf}, journal = {Cleveland Clinic Journal of Medicine} }